Division of Vifor Pharma Group
Latest From Relypsa Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
A Swiss IPO for retail pharmacy and distributor spin-off Galenica Santé has allowed the remaining specialty firm Vifor Pharma to become a pure play pharma with a potential blockbuster potassium binder Veltassa and interests in renal disease, iron replacement and cardio-renal disorders.
- Therapeutic Areas
- Metabolic Disorders
- Renal System
- North America
- Parent & Subsidiaries
- Vifor Pharma Group
- Senior Management
John A Orwin, CEO
Stephen D Harrison, PhD, SVP, CSO
Lance Berman, MD, SVP, CMO
Scott Garland, SVP, Chief Commercial Officer
Camille Landis, VP, Bus. Dev.
- Contact Info
Phone: (650) 421-9500
100 Cardinal Way
Redwood City, CA 94063
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.